Valve replacement

$1.25+ Billion Embolic Protection Device Markets - Global Forecasts from 2021 to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Medical devices, Health, Medicine, Cardiac surgery, Medical specialties, Clinical medicine, American brands, Percutaneous aortic valve replacement, Valve replacement, Medtronic, Aortic valve, Boston Scientific, Catheter

The "Embolic Protection Device Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Embolic Protection Device Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Rising cases of cardiovascular, peripheral, and neurovascular surgeries and heavy investments in the R&D of embolic devices are the prime factors propelling the market growth.
  • The rise in the number of Trans-catheter Aortic Valve Replacement (TAVR) procedures and consumer awareness regarding embolic devices are also contributing toward market development.
  • Prominent/major key market players in the embolic protection devices market include Abbott Laboratories, Boston Scientific Inc., Medtronic Plc., and Gore Medical among others.

China Transcatheter Aortic Valve Replacement (TAVR) Market Report 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Health, General Health, Cardiac surgery, Medical specialties, Medicine, Clinical medicine, Cardiology, Prosthetics, Aortic valve, Percutaneous aortic valve replacement, Valve replacement, Valve Corporation, Artificial heart valve, Expansion valve

The "China Transcatheter Aortic Valve Replacement (TAVR) Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Transcatheter Aortic Valve Replacement (TAVR) Market Insight Report, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Surgical valve is still the basic demand of valve replacement market in China, and domestic biological surgical valve will benefit from the replacement of mechanical valve and imported valve.
  • With the listing of Edward's interventional valve SAPIEN3 in China in 2020, we believe that China's valve industry is at the development base, and the market space needs to be opened urgently.
  • In the way of interventional operation, we think that spherical expansion valve may have more advantages than self-expansion valve.

Tioga Medical, A Shifamed Portfolio Company, Closes $30M In Series B Financing

Retrieved on: 
Wednesday, July 7, 2021
Anatomy, Cardiac surgery, Heart, Medical specialties, Heart valves, Mitral valve, Valve replacement, Heart valve, Edwards Lifesciences

CAMPBELL, Calif., July 7, 2021 /PRNewswire/ -- Tioga Medical, Inc. , a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the initial closing of its committed $30M Series B financing.

Key Points: 
  • CAMPBELL, Calif., July 7, 2021 /PRNewswire/ -- Tioga Medical, Inc. , a Shifamed portfolio company that aims to redefine structural heart valve replacement, announced today the initial closing of its committed $30M Series B financing.
  • "Current valve replacement approaches are either surgically invasive, anatomically limited or procedurally complex, hindering use despite the significant clinical need.
  • Tioga's proprietary technology aims to address these challenges with a less invasive, more adaptable transcatheter intervention," commented Gautam Kainth, Managing Director at TCP.
  • Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach.

Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis

Retrieved on: 
Monday, May 17, 2021
Medical specialties, Cardiac surgery, Clinical medicine, Medicine, Percutaneous aortic valve replacement, Aortic valve replacement, Aortic valve, Aortic stenosis, Valve replacement, Heart valve, Edwards Lifesciences, Aortic valve repair

b'ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT)today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.

Key Points: 
  • b'ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ -- Abbott (NYSE: ABT)today announced it has received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, making the minimally invasive device available for people in Europe with severe aortic stenosis who are at high or extreme surgical risk.
  • With the Navitor valve, the company is advancing TAVI (also referred to as TAVR, or transcatheter aortic valve replacement) therapies with innovations including a unique design to prevent blood leaking around the valve.
  • "This approval strengthens our structural heart portfolio of minimally invasive offerings by providing new options and improvements to treat a life-threatening heart condition.
  • Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk.

New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients

Retrieved on: 
Friday, May 14, 2021
Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Aortic valve replacement, Aortic valve, Percutaneous aortic valve replacement, Aortic stenosis, Valve replacement, Valvular heart disease, Aortic valve repair, Mitral valve replacement

Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.

Key Points: 
  • Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.
  • However, more than half of cardiologists surveyed (53%) feel that their symptomatic severe AS patients are not as informed as they should be about their treatment options.\nThe findings indicate physicians recognize the importance of shared decision making to achieve individualized care for heart valve disease patients.
  • More than 3,400 responses were received from heart valve patients and caregivers.
  • Of the respondents, 94% identified as heart valve patients, 53% identified as aortic stenosis patients.\n'

BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices

Retrieved on: 
Wednesday, April 21, 2021
Biotechnology, Surgery, Medical devices, Health, Cardiology, Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Aortic valve repair, Aortic valve replacement, Bicuspid aortic valve, Aortic valve, Aortic insufficiency, Mitral valve annuloplasty, BAV, Valve replacement

b'BioStable Science & Engineering, Inc. (\xe2\x80\x9cBioStable\xe2\x80\x9d) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair.

Key Points: 
  • b'BioStable Science & Engineering, Inc. (\xe2\x80\x9cBioStable\xe2\x80\x9d) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair.
  • With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to offer surgeons within the European Union a comprehensive portfolio of aortic valve repair solutions that address all forms of aortic valve insufficiency.
  • Approximately 53% of BAV patients require aortic valve surgery within 25 years of being diagnosed [1].
  • Most BAV patients undergo aortic valve replacement between 40 and 60 years of age, subjecting them to increased risk of reoperation or complications associated with valve replacement technologies [2].

Global Aortic Valve (Tissue/Biological, Mechanical) Market Report 2020-2030: Emerging Economies are Key Opportunities Area for Market Players

Retrieved on: 
Friday, April 9, 2021
Medical specialties, Cardiac surgery, Clinical medicine, Circulatory system, Valvular heart disease, Cardiology, Aortic stenosis, Aortic valve, Valve replacement, Aortic insufficiency, Regurgitation, Heart valve

The global aortic valve market is predicted to attain a revenue of $29,146.9 million by 2030, advancing at a 13.2% CAGR during the forecast period (2020-2030)

Key Points: 
  • The global aortic valve market is predicted to attain a revenue of $29,146.9 million by 2030, advancing at a 13.2% CAGR during the forecast period (2020-2030)
    A key factor leading to the growth of the market is the increasing prevalence of aortic regurgitation and aortic stenosis.
  • When procedure is taken into consideration, the aortic valve market is divided into open surgery and minimally invasive surgery (MIS), between which, the MIS division held the major value share of the market in 2019.
  • Some of the common treatments recommended for aortic stenosis are transcatheter aortic valve treatment and surgical valve replacement.
  • Companies operating in the aortic valve market are focusing widely on business mergers, strategic partnerships, product launches, and trial and approvals for remaining competitive in the domain.

JenaValve Technology Welcomes Jane Metcalf as Vice President, Regulatory Affairs and Quality

Retrieved on: 
Thursday, March 18, 2021
Cardiac surgery, Medicine, Medical specialties, Anatomy, Aortic valve replacement, Aortic valve, Percutaneous aortic valve replacement, Regulatory affairs, Valve replacement, Heart valve

IRVINE, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Jane Metcalf to Vice President, Regulatory Affairs and Quality, effective immediately.

Key Points: 
  • IRVINE, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated pericardial transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, announces the appointment of Jane Metcalf to Vice President, Regulatory Affairs and Quality, effective immediately.
  • Ms. Metcalf comes to JenaValve with over 30 years of experience in the medical device industry providing leadership in areas of regulatory affairs, clinical and quality assurance.
  • Jane has a strong track record of successfully developing strategies for worldwide regulatory approvals of innovative devices, said JenaValve CEO John Kilcoyne.
  • Prior to joining JenaValve, Ms. Metcalf served as Vice President of Regulatory Affairs and Quality Assurance at Sonendo Medical.

Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo® Cerebral Protection System

Retrieved on: 
Thursday, February 25, 2021
Cardiology, Biotechnology, Professional services, Health, Pharmaceutical, Venture capital, Medical devices, Research, Surgery, Science, Clinical trials, Medical specialties, Medicine, Clinical medicine, Cardiac surgery, Percutaneous aortic valve replacement, Aortic valve, Valve replacement

Protembis GmbH , a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo Cerebral Protection System.

Key Points: 
  • Protembis GmbH , a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo Cerebral Protection System.
  • The ProtEmbo System is an intra-aortic filter device that deflects embolic material away from the brain during transcatheter aortic valve replacement (TAVR).
  • The objective of the European trial (PROTEMBO C Trial, NCT04618718 ) is to assess the safety and performance of the ProtEmbo System used for embolic protection during TAVR compared to historical data.
  • Protembis is a privately-held, emerging medical device company that has developed the ProtEmbo Cerebral Protection System.

Insights on the Transcatheter Treatment: Procedures and Heart Valve Global Market to 2025 - Key Drivers and Restraints

Retrieved on: 
Friday, February 12, 2021
Medicine, Clinical medicine, Medical specialties, Cardiac surgery, Percutaneous aortic valve replacement, Valvular heart disease, Mitral valve replacement, Minimally invasive procedure, Cardiology, Edwards Lifesciences, Valve replacement

Europe is the second-largest market after the U.S., and there are many established and early-stage companies that are working to enter the European TAVR market by developing improved transcatheter heart valve devices.

Key Points: 
  • Europe is the second-largest market after the U.S., and there are many established and early-stage companies that are working to enter the European TAVR market by developing improved transcatheter heart valve devices.
  • With regard to the European transcatheter treatment device market, it is growing mainly due to improved healthcare infrastructure, increasing prevalence of heart disease, improving diagnosis rates, and growing demand for minimally invasive and catheter-based treatment options.
  • Additionally, the increased patient population and improving diagnosis rate are likely to increase the demand for TAVR/TAVI and TMVR procedures within the region.
  • Japan is an established market in Asia-Pacific, while China and India are emerging markets that are growing rapidly.